Overview: Thai researchers develop artificial intelligence to assess stroke risk and more

Chulalongkorn University researchers develop artificial intelligence to assess stroke risk

A research team from the Faculty of Medicine and Engineering at Chulalongkorn University in Thailand has developed an AI-based web application to assess the risk of stroke in patients due to heart disease.

The tool, called AICute, uses AI to analyze a patient’s brain scans, along with their symptoms and partial history, and generate a stroke risk report within half an hour.

According to a press release, the technology is 92%-94% accurate after testing on a database of 40,000 high-resolution x-ray images. He also achieved “satisfactory” results in a trial at Chulalongkorn Memorial Hospital.

The research team is now starting to test AICute on a large group of real patients and collect additional test data outside of Chula Hospital. An improved version of the AI ​​tool is also expected to be released in the middle of the year. AICute will be released as paid commercial software in the future.

In addition, the research team plans to develop an AI for detecting strokes from other causes, including more databases of X-ray images and angiography.

Remidio receives CE marking for diabetic retinopathy AI detection

Indian medical device company Remidio has received the European CE mark for its artificial intelligence tool for identifying reference diabetic retinopathy (DR).

The smartphone-based Medios AI algorithm is said to be the only smartphone-based algorithm for DR detection that works offline. It screens based on Fundus chamber Remidio NM-FOP inside 10 Seconds.

Thanks to its portability, AI technology can be deployed and scaled up in primary care settings that require minimal expertise, Remidio said.

The CE marking follows the approval of Medios AI by the Medical Sciences Authority of Singapore.

Dr. Axel Baur becomes CEO of Amplify Health.

Amplify Health, a joint venture between AIA Group and Discovery Limited, announced the change from Deputy CEO Dr. Axel Baur to the position of CEO.

Dr. Baur joined the company in March last year after 26 years with McKinsey & Co., where he led the Asian healthcare practice and served as a senior partner in its Hong Kong office.

He will succeed Dr. Jonathan Brumberg, who will remain a non-executive director of Amplify Health and will resume his role as CEO of Vitality Health International and Global Head of Health Insurance at Discovery Limited.